Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?

A. Tefferi

doi:10.1038/leu.2013.112

Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?

A. Tefferi

Hematology

Research output: Contribution to journal › Letter › peer-review

21 Scopus citations

Original language	English (US)
Pages (from-to)	1939-1940
Number of pages	2
Journal	Leukemia
Volume	27
Issue number	9
DOIs	https://doi.org/10.1038/leu.2013.112
State	Published - Sep 2013

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

Access to Document

10.1038/leu.2013.112

Cite this

@article{44d5b0cba8a84609b1851aca19edccbc,

title = "Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?",

author = "A. Tefferi",

year = "2013",

month = sep,

doi = "10.1038/leu.2013.112",

language = "English (US)",

volume = "27",

pages = "1939--1940",

journal = "Leukemia",

issn = "0887-6924",

publisher = "Nature Publishing Group",

number = "9",

}

TY - JOUR

T1 - Nilotinib treatment-associated accelerated atherosclerosis

T2 - When is the risk justified?

AU - Tefferi, A.

PY - 2013/9

Y1 - 2013/9

UR - http://www.scopus.com/inward/record.url?scp=84883741352&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84883741352&partnerID=8YFLogxK

U2 - 10.1038/leu.2013.112

DO - 10.1038/leu.2013.112

M3 - Letter

C2 - 23604230

AN - SCOPUS:84883741352

SN - 0887-6924

VL - 27

SP - 1939

EP - 1940

JO - Leukemia

JF - Leukemia

IS - 9

ER -

Nilotinib treatment-associated accelerated atherosclerosis: When is the risk justified?

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this